GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Peter Lynch Fair Value

Neurotech International (ASX:NTI) Peter Lynch Fair Value : A$-0.25 (As of Jun. 02, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Neurotech International's PEG is 1. Neurotech International's 5-Year TTM EBITDA Growth Rate is 25. Neurotech International's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01. Therefore, the Peter Lynch Fair Value for today is A$-0.25.

As of today (2024-06-02), Neurotech International's share price is A$0.071. Neurotech International's Peter Lynch fair value is A$-0.25. Therefore, Neurotech International's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Neurotech International's Peter Lynch Fair Value or its related term are showing as below:



ASX:NTI's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.675
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Neurotech International Peter Lynch Fair Value Historical Data

The historical data trend for Neurotech International's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Peter Lynch Fair Value Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neurotech International's Peter Lynch Fair Value

For the Medical Devices subindustry, Neurotech International's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Neurotech International's Price-to-Peter-Lynch-Fair-Value falls into.



Neurotech International Peter Lynch Fair Value Calculation

Neurotech International's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-0.01
=-0.25

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neurotech International's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Neurotech International  (ASX:NTI) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Neurotech International's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.071/-0.25
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurotech International Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Neurotech International's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurotech International (ASX:NTI) Business Description

Traded in Other Exchanges
N/A
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend 11-12-2014

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend 08-17-2013

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson 11-09-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend 01-17-2013